Investor Relations
THE SHARE: Change: -0.35 SEK (-1.59%) / Price: 21.70 SEK / Mar 19, 2025, 5:29 pm (CET)
Press Releases
September 23, 2024 15:00 (CEST)
Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics
Regulatory
August 19, 2024 19:00 (CEST)
Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc.
Regulatory
MAR
July 04, 2024 14:45 (CEST)
Genovis completes a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors
Regulatory
Financial Reports
February 14, 2025 08:00 (CET)
Strong momentum: 21% growth in enzyme business and significant improvement in earnings
Regulatory
MAR
Financial Calendar
- Q1 2025
May 21, 2025 - Q2 2025
August 12, 2025 - Q3 2025
November 7, 2025
